Recently, the Drugs Controller General of India (DCGI) has approved Prussian blue insoluble formulations – for radiological and nuclear emergencies.
According to the Defence Ministry, Scott-Edil Pharmacia Ltd, Baddi, Himachal Pradesh, and Skanttr Lifescience LLP, Ahmedabad, Gujarat, were granted the manufacturing and marketing licenses for commercial use of Prussian blue insoluble formulations – developed under the Technology Development Fund (TDF) scheme. The development of these formulations was based on the technology of the Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi – a laboratory of the Defence Research & Development Organisation (DRDO).
The trade name of this drug will be Pru-DecorpTM and PruDecorp-MG. These formulations are utilized for decontaminating Cesium and Thallium and its Active Pharmaceutical Ingredient (API). It is a critical drug used in radiological and nuclear emergencies – based on the World Health Organization (WHO) listings.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details